Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Bioavailability of ABBV-8736 (SC vs IV) in Healthy Volunteers
NCT07413133Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- Feb 2026
- Primary completion
- Jun 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1 trial of ABBV-8736 (2 arms), sponsored by AbbVie Inc. Primary endpoints: Number of Participants with Adverse Events at 3 months, Maximum Observed Serum Concentration of ABBV-8736 at 3 months and 6 more. Started Feb 2026; status: completed.
02
Drugs
ABBV-8736
Beyond the preview
Go deeper on NCT07413133.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07413133.